LU92855I2 - Combinaison de rilpivirine ou une forme thérapeutique equivalente qui en dérive telle que protégée par le brevet de base, tel qu'un sel pharmaceutiquement acceptable de rilpivirine, incluant le sel chlorhydrate de rilpivirine, ténofovir, en particulier le fumarate de ténofovir disoproxil, et l'emtricitabine - Google Patents

Combinaison de rilpivirine ou une forme thérapeutique equivalente qui en dérive telle que protégée par le brevet de base, tel qu'un sel pharmaceutiquement acceptable de rilpivirine, incluant le sel chlorhydrate de rilpivirine, ténofovir, en particulier le fumarate de ténofovir disoproxil, et l'emtricitabine Download PDF

Info

Publication number: LU92855I2
Authority: LU; Luxembourg
Prior art keywords: rilpivirine; tenofovir; emtricitabine; protected; pharmaceutically acceptable
Prior art date: 2003-09-03

Application number

LU92855C

Other languages

English (en)

Original Assignee

Janssen Sciences Ireland Uc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-09-03

Filing date

2015-10-21

Publication date

2015-12-21

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34280181&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LU92855(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2015-10-21 Application filed by Janssen Sciences Ireland Uc filed Critical Janssen Sciences Ireland Uc

2015-12-21 Publication of LU92855I2 publication Critical patent/LU92855I2/fr

Links

229960002814 rilpivirine Drugs 0.000 title 2
YIBOMRUWOWDFLG-ONEGZZNKSA-N rilpivirine Chemical compound CC1=CC(\C=C\C#N)=CC(C)=C1NC1=CC=NC(NC=2C=CC(=CC=2)C#N)=N1 YIBOMRUWOWDFLG-ONEGZZNKSA-N 0.000 title 2
XQSPYNMVSIKCOC-NTSWFWBYSA-N Emtricitabine Chemical compound C1=C(F)C(N)=NC(=O)N1[C@H]1O[C@@H](CO)SC1 XQSPYNMVSIKCOC-NTSWFWBYSA-N 0.000 title 1
229960000366 emtricitabine Drugs 0.000 title 1
KZVVGZKAVZUACK-BJILWQEISA-N rilpivirine hydrochloride Chemical class Cl.CC1=CC(\C=C\C#N)=CC(C)=C1NC1=CC=NC(NC=2C=CC(=CC=2)C#N)=N1 KZVVGZKAVZUACK-BJILWQEISA-N 0.000 title 1
150000003839 salts Chemical class 0.000 title 1
229960004556 tenofovir Drugs 0.000 title 1
SGOIRFVFHAKUTI-ZCFIWIBFSA-N tenofovir (anhydrous) Chemical compound N1=CN=C2N(C[C@@H](C)OCP(O)(O)=O)C=NC2=C1N SGOIRFVFHAKUTI-ZCFIWIBFSA-N 0.000 title 1
229960004693 tenofovir disoproxil fumarate Drugs 0.000 title 1
VCMJCVGFSROFHV-WZGZYPNHSA-N tenofovir disoproxil fumarate Chemical compound OC(=O)\C=C\C(O)=O.N1=CN=C2N(C[C@@H](C)OCP(=O)(OCOC(=O)OC(C)C)OCOC(=O)OC(C)C)C=NC2=C1N VCMJCVGFSROFHV-WZGZYPNHSA-N 0.000 title 1
230000001225 therapeutic effect Effects 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Epidemiology (AREA)
Immunology (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Engineering & Computer Science (AREA)
Virology (AREA)
Bioinformatics & Cheminformatics (AREA)
Molecular Biology (AREA)
AIDS & HIV (AREA)
Tropical Medicine & Parasitology (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Plural Heterocyclic Compounds (AREA)

LU92855C 2003-09-03 2015-10-21 Combinaison de rilpivirine ou une forme thérapeutique equivalente qui en dérive telle que protégée par le brevet de base, tel qu'un sel pharmaceutiquement acceptable de rilpivirine, incluant le sel chlorhydrate de rilpivirine, ténofovir, en particulier le fumarate de ténofovir disoproxil, et l'emtricitabine LU92855I2 (fr)

Applications Claiming Priority (8)

Application Number	Priority Date	Filing Date	Title
US49977103P	2003-09-03	2003-09-03
EP03103275		2003-09-03
EP03103319		2003-09-08
EP03103335		2003-09-10
EP03103668		2003-10-02
US50848603P	2003-10-03	2003-10-03
PCT/EP2004/052028 WO2005021001A1 (fr)	2003-09-03	2004-09-03	Combinaisons d'une pyrimidine renfermant nnrti avec des inhibiteurs de rt
EP04787096.9A EP1663240B2 (fr)	2003-09-03	2004-09-03	Combinaison d'un inhibiteur non-nucleosidique de la transcriptase inverse (nnrti) contenant une pyrimidine avec un inhibiteur nucleosidique de la transcriptase inverse (nrti)

Publications (1)

Publication Number	Publication Date
LU92855I2 true LU92855I2 (fr)	2015-12-21

Family

ID=34280181

Family Applications (3)

Application Number	Title	Priority Date	Filing Date
LU92853C LU92853I2 (fr)	2003-09-03	2015-10-20	Combinaison de rilpivirine ou une forme thérapeutique équivalente qui en dérive telle que protégée par le brevet de base, tel qu'un sel pharmaceutiquement acceptable de rilpivirine, incluant le sel chlorhydrate de rilpivirine et l'emtricitabine
LU92854C LU92854I2 (fr)	2003-09-03	2015-10-21	Combinaison de rilpivirine ou une forme thérapeutique équivalente qui en dérive telle que protégé par le brevet de base, tel qu'un sel pharmaceutiquement acceptable de rilpivirine, incluant le sel chlorhydrate de rilpivirine, et ténofovir, en particulier le fumarate de ténofovir disoproxil
LU92855C LU92855I2 (fr)	2003-09-03	2015-10-21	Combinaison de rilpivirine ou une forme thérapeutique equivalente qui en dérive telle que protégée par le brevet de base, tel qu'un sel pharmaceutiquement acceptable de rilpivirine, incluant le sel chlorhydrate de rilpivirine, ténofovir, en particulier le fumarate de ténofovir disoproxil, et l'emtricitabine

Family Applications Before (2)

Application Number	Title	Priority Date	Filing Date
LU92853C LU92853I2 (fr)	2003-09-03	2015-10-20	Combinaison de rilpivirine ou une forme thérapeutique équivalente qui en dérive telle que protégée par le brevet de base, tel qu'un sel pharmaceutiquement acceptable de rilpivirine, incluant le sel chlorhydrate de rilpivirine et l'emtricitabine
LU92854C LU92854I2 (fr)	2003-09-03	2015-10-21	Combinaison de rilpivirine ou une forme thérapeutique équivalente qui en dérive telle que protégé par le brevet de base, tel qu'un sel pharmaceutiquement acceptable de rilpivirine, incluant le sel chlorhydrate de rilpivirine, et ténofovir, en particulier le fumarate de ténofovir disoproxil

Country Status (24)

Country	Link
US (9)	US20080200435A1 (fr)
EP (1)	EP1663240B2 (fr)
JP (3)	JP5507791B2 (fr)
KR (1)	KR20060090658A (fr)
CN (1)	CN101060844B (fr)
AP (1)	AP2109A (fr)
AU (5)	AU2004268390B2 (fr)
BE (1)	BE2015C053I2 (fr)
CA (1)	CA2537095C (fr)
CY (5)	CY2015040I2 (fr)
FI (1)	FI1663240T4 (fr)
FR (5)	FR15C0072I2 (fr)
HR (1)	HRP20150798T4 (fr)
HU (5)	HUS1500054I1 (fr)
IL (2)	IL173438A (fr)
LT (2)	LTPA2016045I1 (fr)
LU (3)	LU92853I2 (fr)
MX (1)	MXPA06002437A (fr)
MY (1)	MY169670A (fr)
NL (2)	NL300781I2 (fr)
NO (6)	NO334877B1 (fr)
NZ (1)	NZ545306A (fr)
PL (1)	PL1663240T5 (fr)
WO (1)	WO2005021001A1 (fr)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JO3429B1 (ar)	2001-08-13	2019-10-20	Janssen Pharmaceutica Nv	مشتقات برميدينات مثبطة فيروس الايدز
MY169670A (en)	2003-09-03	2019-05-08	Tibotec Pharm Ltd	Combinations of a pyrimidine containing nnrti with rt inhibitors
US8101629B2 (en)	2001-08-13	2012-01-24	Janssen Pharmaceutica N.V.	Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile
US7638522B2 (en)	2001-08-13	2009-12-29	Janssen Pharmaceutica N.V.	Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino] benzonitrile
US7399856B2 (en)	2002-08-09	2008-07-15	Janssen Pharmaceutica N.V.	Processes for the preparation of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-2pyrimidinyl]amino]benzonitrile
PT1583542E (pt)	2003-01-14	2008-09-17	Gilead Sciences Inc	Composições e métodos para terapia de combinação antiviral
ATE550074T1 (de) *	2004-09-02	2012-04-15	Janssen Pharmaceutica Nv	Fumarat aus 4-((4-((4-(2-cyanoethenyl)-2,6- dimethylphenyl amino -2-pyrimidinyl amino benzonitril
SG155885A1 (en) *	2004-09-02	2009-10-29	Janssen Pharmaceutica Nv	Furamate of 4-((4-((4-(2-cyanoethenyl)-2,6-dimethylphenyl)amino)-2- pyrimidinyl)amino)benzonitrile
WO2006024667A1 (fr) *	2004-09-02	2006-03-09	Janssen Pharmaceutica N.V.	Furamate de 4- ( (4- ( (4- (2-cyanoethenyl) -2, 6-dimethylphenyl) amino) -2-pyrimidinyl) amino) benzonitrile
CA2577288C (fr) *	2004-09-02	2010-11-30	Janssen Pharmaceutica N.V.	Chlorhydrate de 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethyl-phenyl]amino]-2-pyrimidinyl]amino]benzonitrile
PT1632232E (pt) *	2004-09-02	2011-08-02	Janssen Pharmaceutica Nv	Sal de 4-[[4-[[4-(2-cianoetenil)-2,6-dimetilfenil]amino]- 2-pirimidinil]amino]benzonitrilo
TWI457136B (zh) *	2005-04-04	2014-10-21	Tibotec Pharm Ltd	Ｈｉｖ-感染之預防
TWI471145B (zh)	2005-06-13	2015-02-01	Bristol Myers Squibb & Gilead Sciences Llc	單一式藥學劑量型
TWI375560B (en) *	2005-06-13	2012-11-01	Gilead Sciences Inc	Composition comprising dry granulated emtricitabine and tenofovir df and method for making the same
ATE474560T1 (de) *	2005-12-14	2010-08-15	Cipla Ltd	Pharmazeutische kombination aus nucleotid und nucleosid-reverse-transkriptase-hemmern (wie tenofovir und lamivudin) in verschiedenen teilen der dosiereinheit
AR059097A1 (es) *	2006-01-20	2008-03-12	Tibotec Pharm Ltd	Tratamiento a largo plazo de la infeccion por vih
US9044509B2 (en) *	2006-02-03	2015-06-02	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Inhibition of HIV infection through chemoprophylaxis
FR2903312B1 (fr)	2006-07-05	2008-09-26	Univ Aix Marseille Ii	Utilisation d'inhibiteurs d'hmg-coa reductase et de farnesyl-pyrophosphate synthase dans la preparation d'un medicament
AR065720A1 (es)	2007-03-14	2009-06-24	Tibotec Pharm Ltd	Polvos para reconstitucion que comprenden rilpivirina dispersos en ciertos polimeros. uso. proceso.
AU2008353145B2 (en) *	2008-01-03	2013-09-12	Universite D' Aix-Marseille	Bitherapy and tritherapy used for treating an HIV-positive patient
MY160360A (en) *	2008-12-24	2017-02-28	Janssen Sciences Ireland Uc	Implantable devices for treating hiv
ES2600878T3 (es)	2009-12-21	2017-02-13	Janssen Sciences Ireland Uc	Implante removible, degradable, para la liberación prolongada de un compuesto activo
EP3351249A1 (fr)	2010-01-27	2018-07-25	VIIV Healthcare Company	Thérapie antivirale
NZ610729A (en)	2010-11-19	2015-10-30	Gilead Sciences Inc	Therapeutic compositions comprising rilpivirine hcl and tenofovir disoproxil fumarate
WO2012125993A1 (fr)	2011-03-17	2012-09-20	Teva Pharmaceutical Industries Ltd.	Formes à l'état solide de base rilpivirine et sels de rilpivirine
EP2755959B1 (fr) *	2011-09-16	2018-05-16	Hetero Research Foundation	Chlorhydrate de rilpivirine
EA030003B1 (ru)	2012-12-21	2018-06-29	Джилид Сайэнс, Инк.	Полициклическое карбамоилпиридоновое соединение и его фармацевтическое применение для лечения вич-инфекции
CN113546052A (zh)	2015-11-09	2021-10-26	吉利德科学公司	治疗人免疫缺陷病毒的治疗组合物
MA46563B1 (fr)	2016-10-24	2024-01-31	Janssen Sciences Ireland Unlimited Co	Compositions dispersibles
US20210128554A1 (en) *	2016-12-23	2021-05-06	Temple University - Of The Commonwealth System Of Higher Education	Anti-flaviviridae activity of anti-retroviral non-nucleoside (nnrtis) and nucleoside reverse transcriptase inhibitors (nnrtis)
RU2019136678A (ru) *	2017-04-18	2021-05-18	Сипла Лимитед	Комбинированная терапия для применения в лечении ретровирусных инфекций
WO2019021319A1 (fr) *	2017-07-27	2019-01-31	Cipla Limited	Compositions pharmaceutiques
WO2021104487A1 (fr)	2019-11-29	2021-06-03	Aptorum Therapeutics Limited	Composition comprenant de la rilpivirine et son utilisation pour le traitement de tumeurs ou du cancer

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5182111A (en)	1987-11-17	1993-01-26	Boston University Research Foundation	In vivo delivery of active factors by co-cultured cell implants
US5047407A (en)	1989-02-08	1991-09-10	Iaf Biochem International, Inc.	2-substituted-5-substituted-1,3-oxathiolanes with antiviral properties
GB8815265D0 (en)	1988-06-27	1988-08-03	Wellcome Found	Therapeutic nucleosides
US5368864A (en)	1988-11-25	1994-11-29	Henning Berlin Gmbh Chemie- Und Pharmawerk	Formulation of oxypurinol and/or its alkali and alkaline earth salts
MY104575A (en)	1989-12-22	1994-04-30	The Wellcome Foundation Ltd	Therapeutic nucleosides.
DK0489181T3 (da)	1990-07-19	1996-11-18	Otsuka Pharma Co Ltd	Fast præparat
US5145684A (en)	1991-01-25	1992-09-08	Sterling Drug Inc.	Surface modified drug nanoparticles
WO1993009176A2 (fr)	1991-10-29	1993-05-13	Clover Consolidated, Limited	Polysaccharides, polycations et lipides reticulables destines a l'encapsulation et la liberation de medicaments
AU4079593A (en)	1992-05-13	1993-12-13	Wellcome Foundation Limited, The	Therapeutic combinations
JPH06316524A (ja)	1992-09-11	1994-11-15	Naoyuki Inoue	抗エイズウイルス剤
TW401303B (en)	1994-07-01	2000-08-11	Janssen Pharmaceutica Nv	Anti-HIV triple combination
IT1281502B1 (it) *	1995-06-13	1998-02-18	Sardinian Antiviral Research C	Impiego di un inibitore non nucleosidico della trascrittasi inversa in associazione con inibitori nucleosidici per il trattamento della
US6045829A (en)	1997-02-13	2000-04-04	Elan Pharma International Limited	Nanocrystalline formulations of human immunodeficiency virus (HIV) protease inhibitors using cellulosic surface stabilizers
WO2001021154A2 (fr)	1999-09-21	2001-03-29	Rtp Pharma Inc.	Compositions particulaires, a surface modifiee, de substances biologiquement actives
US6743446B2 (en)	1999-12-15	2004-06-01	The Ohio State University Research Foundation	Methods for stabilizing biologically active agents encapsulated in biodegradable controlled-release polymers
TWI284048B (en)	2000-01-27	2007-07-21	Zentaris Ag	Compressed microparticles for dry injection
CA2404687A1 (fr)	2000-03-30	2001-10-11	Nemichand B. Jain	Granules a liberation lente contenant de la stavudine
US20040115268A1 (en)	2000-04-26	2004-06-17	Control Delivery Systems, Inc.	Systemic delivery of antiviral agents
DE10050199A1 (de)	2000-10-11	2002-04-25	Ethicon Gmbh	Flächiges Implantat mit im Ultraschall detektierbaren Elementen
PL362979A1 (en)	2000-12-11	2004-11-02	Takeda Chemical Industries, Ltd.	Medicinal compositions improved in solublity in water
MXPA03011784A (es)	2001-06-22	2004-04-02	Pfizer Prod Inc	Composiciones farmaceuticas de dispersiones de farmacos y polimeros neutros.
MY169670A (en)	2003-09-03	2019-05-08	Tibotec Pharm Ltd	Combinations of a pyrimidine containing nnrti with rt inhibitors
JO3429B1 (ar) *	2001-08-13	2019-10-20	Janssen Pharmaceutica Nv	مشتقات برميدينات مثبطة فيروس الايدز
WO2003043586A2 (fr)	2001-11-20	2003-05-30	Advanced Inhalation Research, Inc.	Compositions destinees a la liberation de produits a action continue
US7399856B2 (en)	2002-08-09	2008-07-15	Janssen Pharmaceutica N.V.	Processes for the preparation of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-2pyrimidinyl]amino]benzonitrile
WO2004022033A1 (fr)	2002-09-04	2004-03-18	Microchips, Inc.	Technique et dispositif d'apport commande d'hormone parathyroide
ATE361059T1 (de)	2002-11-08	2007-05-15	Glaxo Group Ltd	Antivirale zusammensetzungen
MXPA05005146A (es)	2002-11-15	2005-07-22	Tibotec Pharm Ltd	Indolpiridinio sustituido como compuestos antiinfecciosos.
AU2002350719A1 (en)	2002-11-29	2004-06-23	Janssen Pharmaceutica N.V.	Pharmaceutical compositions comprising a basic respectively acidic drug compound, a surfactant and a physiologically tolerable water-soluble acid respectively base
EP1597237B1 (fr)	2003-02-07	2016-07-27	Janssen Pharmaceutica NV	Dérivés de pyrimidine utiles dans la prévention des infections par le VIH
KR100629771B1 (ko)	2004-01-27	2006-09-28	씨제이 주식회사	결정성이 감소되거나 무정형화된 올티프라즈의 제조방법
WO2005123076A2 (fr)	2004-06-08	2005-12-29	Vertex Pharmaceuticals, Inc.	Compositions pharmaceutiques
MY191349A (en)	2004-08-27	2022-06-17	Bayer Pharmaceuticals Corp	New pharmaceutical compositions for the treatment of hyper-proliferative disorders
CA2577288C (fr)	2004-09-02	2010-11-30	Janssen Pharmaceutica N.V.	Chlorhydrate de 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethyl-phenyl]amino]-2-pyrimidinyl]amino]benzonitrile
PT1632232E (pt)	2004-09-02	2011-08-02	Janssen Pharmaceutica Nv	Sal de 4-[[4-[[4-(2-cianoetenil)-2,6-dimetilfenil]amino]- 2-pirimidinil]amino]benzonitrilo
EP2623095A1 (fr)	2004-11-16	2013-08-07	Elan Pharma International Limited	Formulations injectables de nanoparticules d'olanzapine
TWI457136B (zh)	2005-04-04	2014-10-21	Tibotec Pharm Ltd	Ｈｉｖ-感染之預防
AR056652A1 (es)	2005-04-11	2007-10-17	Tibotec Pharm Ltd	Derivados de (1,10-b dihidro-2-(aminoalquil-fenil) -5h-pirazolo (1,5-c) (1,3)benzoxazin-5-il) fenilmetanona y su uso en la fabricacion de un medicamento
CA2603851A1 (fr)	2005-04-11	2006-10-19	The Board Of Trustees Of The Leland Stanford Junior Unversity	Structure multicouche possedant une configuration predeterminee comprenant un agent
US20090142401A1 (en)	2005-06-07	2009-06-04	Leah Elizabeth Appel	Multiparticulates comprising low-solubility drugs and carriers that result in rapid drug release
EP1912730A2 (fr)	2005-07-28	2008-04-23	Isp Investments Inc.	Procede d'amelioration des caracteristiques de poudres sechees par atomisation et de materiaux granules, et produits obtenus par ce procede
AR059097A1 (es)	2006-01-20	2008-03-12	Tibotec Pharm Ltd	Tratamiento a largo plazo de la infeccion por vih
PT3366278T (pt)	2006-06-23	2024-10-21	Janssen Sciences Ireland Unlimited Co	Suspensões aquosas de tmc278
US20080081064A1 (en)	2006-09-28	2008-04-03	Surmodics, Inc.	Implantable Medical Device with Apertures for Delivery of Bioactive Agents
AR065720A1 (es)	2007-03-14	2009-06-24	Tibotec Pharm Ltd	Polvos para reconstitucion que comprenden rilpivirina dispersos en ciertos polimeros. uso. proceso.
HRP20131128T1 (hr)	2007-07-12	2013-12-20	Janssen R&D Ireland	Kristalni oblik (e) 4-[[4-[[4-(2-cijanoetenil)-2,6-dimetilfenil]amino]-2-pirimidinil]amino]benzonitrila
US20090123508A1 (en)	2007-10-04	2009-05-14	Boston Scientific Scimed, Inc.	Implantable Drug Depot for Intrathecal Drug Delivery System for Pain Management
EP2358198A4 (fr)	2008-10-24	2012-11-14	Concert Pharmaceuticals Inc	Dérivés d'hydroxyéthylaminosulfonamide

2004
- 2004-09-02 MY MYPI20043578A patent/MY169670A/en unknown
- 2004-09-03 AP AP2006003551A patent/AP2109A/en active
- 2004-09-03 CA CA2537095A patent/CA2537095C/fr not_active Expired - Lifetime
- 2004-09-03 PL PL04787096.9T patent/PL1663240T5/pl unknown
- 2004-09-03 KR KR1020067003074A patent/KR20060090658A/ko not_active Ceased
- 2004-09-03 JP JP2006525150A patent/JP5507791B2/ja not_active Expired - Lifetime
- 2004-09-03 US US10/570,228 patent/US20080200435A1/en not_active Abandoned
- 2004-09-03 MX MXPA06002437A patent/MXPA06002437A/es active IP Right Grant
- 2004-09-03 EP EP04787096.9A patent/EP1663240B2/fr not_active Expired - Lifetime
- 2004-09-03 NZ NZ545306A patent/NZ545306A/en not_active IP Right Cessation
- 2004-09-03 AU AU2004268390A patent/AU2004268390B2/en not_active Expired
- 2004-09-03 CN CN2004800254267A patent/CN101060844B/zh not_active Expired - Lifetime
- 2004-09-03 WO PCT/EP2004/052028 patent/WO2005021001A1/fr not_active Ceased
2006
- 2006-01-30 IL IL173438A patent/IL173438A/en active Protection Beyond IP Right Term
- 2006-03-27 NO NO20061374A patent/NO334877B1/no active Protection Beyond IP Right Term
2009
- 2009-10-07 US US12/574,881 patent/US8841310B2/en not_active Expired - Lifetime
2011
- 2011-03-14 AU AU2011201123A patent/AU2011201123B2/en not_active Expired
- 2011-05-24 IL IL213104A patent/IL213104A/en active IP Right Grant
- 2011-10-12 JP JP2011224982A patent/JP2012051915A/ja not_active Withdrawn
2014
- 2014-06-26 AU AU2014203484A patent/AU2014203484B2/en active Active
- 2014-08-07 US US14/454,045 patent/US20140349971A1/en not_active Abandoned
- 2014-10-31 JP JP2014222770A patent/JP5820045B2/ja not_active Expired - Lifetime
- 2014-12-18 NO NO2014030C patent/NO2014030I1/no unknown
- 2014-12-18 NO NO2014032C patent/NO2014032I1/no unknown
- 2014-12-18 NO NO2014031C patent/NO2014031I1/no not_active IP Right Cessation
2015
- 2015-06-19 US US14/744,501 patent/US20150283135A1/en not_active Abandoned
- 2015-07-20 HR HRP20150798TT patent/HRP20150798T4/hr unknown
- 2015-10-20 LU LU92853C patent/LU92853I2/fr unknown
- 2015-10-20 NL NL300781C patent/NL300781I2/nl unknown
- 2015-10-21 FR FR15C0072C patent/FR15C0072I2/fr active Active
- 2015-10-21 CY CY2015040C patent/CY2015040I2/el unknown
- 2015-10-21 CY CY2015038C patent/CY2015038I2/el unknown
- 2015-10-21 HU HUS1500054C patent/HUS1500054I1/hu unknown
- 2015-10-21 FR FR15C0073C patent/FR15C0073I2/fr active Active
- 2015-10-21 LU LU92854C patent/LU92854I2/fr unknown
- 2015-10-21 FR FR15C0071C patent/FR15C0071I2/fr active Active
- 2015-10-21 BE BE2015C053C patent/BE2015C053I2/fr unknown
- 2015-10-21 LU LU92855C patent/LU92855I2/fr unknown
- 2015-10-21 NL NL300768C patent/NL300768I2/nl unknown
- 2015-10-21 HU HUS1500052C patent/HUS1500052I1/hu unknown
- 2015-10-21 CY CY2015039C patent/CY2015039I1/el unknown
- 2015-10-21 HU HUS1500053C patent/HUS1500053I1/hu unknown
2016
- 2016-08-05 AU AU2016210733A patent/AU2016210733B2/en active Active
- 2016-12-19 US US15/383,076 patent/US20170100398A1/en not_active Abandoned
- 2016-12-20 NO NO2016025C patent/NO2016025I1/no unknown
- 2016-12-20 CY CY2016048C patent/CY2016048I2/el unknown
- 2016-12-20 FR FR16C1022C patent/FR16C1022I1/fr active Active
- 2016-12-20 HU HUS1600059C patent/HUS1600059I1/hu unknown
- 2016-12-20 LT LTPA2016045C patent/LTPA2016045I1/lt unknown
- 2016-12-20 CY CY2016049C patent/CY2016049I2/el unknown
- 2016-12-20 LT LTPA2015035C patent/LTC1663240I2/lt unknown
- 2016-12-20 HU HUS1600058C patent/HUS1600058I1/hu unknown
- 2016-12-20 NO NO2016026C patent/NO2016026I1/no unknown
- 2016-12-20 FI FIEP04787096.9T patent/FI1663240T4/fi active
- 2016-12-20 FR FR16C1024C patent/FR16C1024I1/fr active Active
2018
- 2018-04-11 US US15/950,548 patent/US20180228800A1/en not_active Abandoned
2019
- 2019-02-06 AU AU2019200813A patent/AU2019200813A1/en not_active Abandoned
- 2019-03-21 US US16/360,693 patent/US20190216807A1/en not_active Abandoned
2020
- 2020-02-07 US US16/784,404 patent/US20200171027A1/en not_active Abandoned
2021
- 2021-09-13 US US17/472,870 patent/US20220008417A1/en not_active Abandoned

Also Published As

Publication number	Publication date
CY2016049I1 (el)	2017-07-12
AU2004268390B2 (en)	2011-03-31
US20140349971A1 (en)	2014-11-27
CY2015039I2 (el)	2016-08-31
CY2015040I1 (el)	2016-08-31
NO2014030I1 (no)	2015-01-05
AU2014203484B2 (en)	2016-09-29
AU2004268390A1 (en)	2005-03-10
LU92854I2 (fr)	2015-12-21
EP1663240B1 (fr)	2015-04-22
JP2015044839A (ja)	2015-03-12
HUS1500053I1 (hu)	2016-03-29
AU2016210733B2 (en)	2018-11-08
CA2537095C (fr)	2012-05-29
AU2011201123A1 (en)	2011-04-07
NL300781I1 (fr)	2016-04-19
PL1663240T3 (pl)	2015-10-30
US20180228800A1 (en)	2018-08-16
AU2019200813A1 (en)	2019-02-28
MY169670A (en)	2019-05-08
HUS1500054I1 (hu)	2016-03-29
CY2016048I1 (el)	2017-07-12
CN101060844B (zh)	2012-01-04
NL300768I2 (nl)	2023-08-09
AU2016210733A1 (en)	2016-08-25
NO2014032I2 (no)	2014-12-18
FR15C0073I1 (fr)	2015-04-12
IL173438A (en)	2012-03-29
CY2015038I1 (el)	2016-08-31
NO2014030I2 (no)	2014-12-18
FI1663240T4 (fi)	2023-04-25
FR15C0073I2 (fr)	2016-02-12
AU2011201123B2 (en)	2013-10-10
FR15C0071I1 (fr)	2015-04-12
NO2014031I1 (no)	2015-01-05
BE2015C053I2 (fr)	2023-12-14
US20200171027A1 (en)	2020-06-04
LTPA2016045I1 (lt)	2017-01-10
AP2109A (en)	2010-02-26
HRP20150798T4 (hr)	2023-06-09
US20100029591A1 (en)	2010-02-04
US20220008417A1 (en)	2022-01-13
FR15C0072I1 (fr)	2015-04-12
NZ545306A (en)	2009-11-27
NO2016025I1 (fr)	2016-12-20
CY2016048I2 (el)	2017-07-12
FR16C1022I1 (fr)	2017-02-03
CY2016049I2 (el)	2017-07-12
AU2014203484A1 (en)	2014-07-17
US20190216807A1 (en)	2019-07-18
HUS1500052I1 (hu)	2016-03-29
NO20061374L (no)	2006-03-27
US8841310B2 (en)	2014-09-23
LTC1663240I2 (lt)	2022-05-25
EP1663240A1 (fr)	2006-06-07
NO2016026I1 (no)	2016-12-20
HK1092698A1 (en)	2007-02-16
NL300781I2 (fr)	2016-04-19
US20080200435A1 (en)	2008-08-21
AP2006003551A0 (en)	2006-04-30
JP5507791B2 (ja)	2014-05-28
JP2012051915A (ja)	2012-03-15
JP2007520443A (ja)	2007-07-26
IL213104A0 (en)	2011-07-31
US20170100398A1 (en)	2017-04-13
NO2014032I1 (no)	2015-01-05
CN101060844A (zh)	2007-10-24
HUS1600059I1 (hu)	2017-02-28
FR15C0072I2 (fr)	2019-05-17
NL300768I1 (fr)	2015-12-16
WO2005021001A1 (fr)	2005-03-10
HUS1600058I1 (hu)	2017-02-28
LU92853I2 (fr)	2015-12-21
LTPA2016044I1 (lt)	2017-01-10
IL173438A0 (en)	2006-06-11
HRP20150798T1 (hr)	2015-09-11
CY2015038I2 (el)	2016-08-31
FR16C1024I1 (fr)	2017-02-03
CY2015039I1 (el)	2016-08-31
CY2015040I2 (el)	2016-08-31
KR20060090658A (ko)	2006-08-14
IL213104A (en)	2016-02-29
US20150283135A1 (en)	2015-10-08
EP1663240B2 (fr)	2023-03-01
CA2537095A1 (fr)	2005-03-10
NO334877B1 (no)	2014-06-23
JP5820045B2 (ja)	2015-11-24
FR15C0071I2 (fr)	2016-02-12
NO2014031I2 (no)	2014-12-18
MXPA06002437A (es)	2006-06-20
PL1663240T5 (pl)	2024-02-26

Publication	Publication Date	Title
LU92854I2 (fr)	2015-12-21	Combinaison de rilpivirine ou une forme thérapeutique équivalente qui en dérive telle que protégé par le brevet de base, tel qu'un sel pharmaceutiquement acceptable de rilpivirine, incluant le sel chlorhydrate de rilpivirine, et ténofovir, en particulier le fumarate de ténofovir disoproxil
WO2002042462A3 (fr)	2003-06-19	Agents therapeutiques et methodes d'utilisation de ces agents therapeutiques pour traiter une maladie amyloidogenique
BG108269A (en)	2004-12-30	Pyrazolopyrimidines as therapeutic agents
BR0308452A (pt)	2006-06-06	composições farmacêuticas e métodos de preparação de composição farmacêutica
BG108268A (en)	2005-04-30	Pyrazolopyrimidines as therapeutic agents
ATE454138T1 (de)	2010-01-15	Tablette mit modifizierter freisetzung von bupropion hydrochlorid
EP1796632A4 (fr)	2009-03-11	Formulations a base d'organogel destinee a des applications therapeutiques
UA90518C2 (ru)	2010-05-11	Фармацевтическая композиция в форме таблетки, которая имеет улучшеное всасывание при трансбукальном введение, которая содержит наркотический активный ингредиент и амин
EP1827468A4 (fr)	2009-08-05	Acetate de leuprolide et inhibiteurs de l'acetylcholinesterase ou antagonistes des recepteurs nmda pour le traitement de la maladie d'alzheimer
BR0209020A (pt)	2004-08-10	Composição farmacêutica de polialilamina
MY117971A (en)	2004-08-30	Denaturants for sympathomimetic amine salts
DK1296671T3 (da)	2008-06-16	Gabapentinanaloger til sövnforstyrrelser
EP1450803A4 (fr)	2008-09-03	Nouvelles utilisations pour des agents therapeutiques antipaludiques
MXPA05007609A (es)	2005-09-30	Antagonista de un receptor sensible al calcio.
DK1471892T3 (da)	2009-12-07	Transdermalt terapeutisk system til parkinsons sygdom, der inducerer höje rotigotinplasmaniveauer
TNSN04071A1 (fr)	2006-06-01	Derives de 3-azabicyclo [3.1.0] hexane servant d'antagonistes des recepteurs d'opioides
WO2007038112A3 (fr)	2007-12-06	Composition pharmaceutique conçue pour ameliorer la fonction cognitive
IL157540A0 (en)	2004-03-28	N-(aryl)-2-arylethenesulphonamides and therapeutic uses thereof
SE0102440D0 (sv)	2001-07-05	New compound
SG153661A1 (en)	2009-07-29	Formulation and methods for the treatment of thrombocythemia
PL369736A1 (en)	2005-05-02	New medicinal compositions on the basis of anticholinergic agents and egfr kinase inhibitors
EP1411897A4 (fr)	2010-08-11	Compositions et methodes d'administration intracellulaire
ITRM20030485A0 (it)	2003-10-22	Composizione a base di citicolina in associazione con vitamine per laprevenzione ed il trattamento di patolgie oculari.
MXPA01009032A (es)	2004-11-10	Composicion farmaceutica para la prevencion o el tratamiento de una enfermedad asociada con un exceso se la produccion de il-12.
IL172213A0 (en)	2009-02-11	Compounds useful in the therapy of alzheimer's disease and formulations containing them